Search Results
Mar 09, 2026, 09:00 ET Orsini Selected by Immedica Pharma US Inc. as Exclusive Specialty Pharmacy and Hub Services Partner for LOARGYS® (pegzilarginase-nbln)
trial.About OrsiniProviding patients with comprehensive and compassionate care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary
More news about: Orsini
Mar 09, 2026, 08:30 ET Klotho Neurosciences Announces Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML Effective March 12, 2026
of the Skaergaard Project in Southeast Greenland, one of the largest undeveloped palladium, gold, and platinum deposits in the world; and 2) Cell and Gene Therapy, including Klotho's KLTO-202 primary indication for ALS. The Company holds, through its acquisition of Greenland Mines Corp., an 80% interest
More news about: Klotho Neurosciences, Inc.
Mar 08, 2026, 16:43 ET RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things,
More news about: THE ROSEN LAW FIRM, P. A.
Mar 07, 2026, 11:45 ET Kessler Topaz Meltzer & Check, LLP Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE); April 13, 2026, Lead Plaintiff Deadline
COMPLAINT ALLEGATION SUMMARY:uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease (HD). uniQure's leading drug candidate is AMT-130, a novel gene therapy being developed to slow the progression of HD. During the Class Period, uniQure
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 06, 2026, 09:00 ET PPMD Joins Cooperative International Neuromuscular Research Group, Global Sponsors to Advance Expanded Duchenne Natural History Study
Neuromuscular Research Group (CINRG) to advance the expanded Duchenne Natural History Study (eDNHS) study. Joining PPMD in support of the eDNHS study is Insmed Gene Therapy, LLC; ITF Therapeutics, LLC; NS Pharma, Inc; Santhera Pharmaceuticals (Switzerland), Ltd; Sarepta Therapeutics, Inc; Solid Biosciences Inc;
More news about: Parent Project Muscular Dystrophy (PPMD)
Mar 06, 2026, 08:48 ET RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026
2026, REGENXBIO issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular
More news about: Faruqi & Faruqi, LLP
Mar 06, 2026, 07:03 ET CARsgen Therapeutics Announces 2025 Annual Results
Biotech Limited.In vivo CAR-T product candidates in developmentApart from CAR T-cell products manufactured via in vitro gene editing, CARsgen is also developing in vivo CAR T-cell products. CARsgen's proprietary lentiviral-based CARvivo™ platform demonstrates excellent
More news about: CARsgen Therapeutics
Mar 05, 2026, 16:59 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX
2026, Regenxbio issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular
More news about: Pomerantz LLP
Mar 05, 2026, 16:59 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE
from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington's disease (HD)." The press release stated that, "based on the discussions at the meeting, uniQure believes that the FDA currently
More news about: Pomerantz LLP
Mar 05, 2026, 14:52 ET Herpes Virus Fluidizes Cell Nuclei to Multiply Faster
nuclei for viral replication because it attaches to the proteins that get human cells ready for transcription, the process by which a stretch of the gene code gets read by the cell's machinery to pass on its message. For any piece of code to be read, however, its surrounding chromatin must get the signal
More news about: NYU Langone
Mar 05, 2026, 14:25 ET RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST
vs. Reality: The REGENXBIO Gene Therapy Performance GapNEW YORK, March 5, 2026 /PRNewswire/ -- "Very promising results." That is how REGENXBIO, Inc. (NASDAQ: RGNX) characterized its RGX-111 gene therapy candidate as recently
More news about: SueWallSt.com
Mar 05, 2026, 12:25 ET Shared origins illuminate potential dependency across brain tumor types
cell types involved.Once the researchers created their atlas, they measured gene expression in the cohort of rare tumor samples from 38 patients and compared it to normal pineal gland development. By measuring gene expression using single-cell RNA-sequencing, they found that a population of early
More news about: St. Jude Children's Research Hospital
Mar 05, 2026, 10:16 ET Lipid Nanoparticles Market to Reach $3.1 Billion, Globally, by 2033 at 13.1% CAGR: Allied Market Research
mRNA-based therapeutics and vaccines, and continuous innovations in nanomedicine. In addition, expanding pharmaceutical and biotechnology research, growth of gene therapy and oncology pipelines, and rising investment in scalable manufacturing technologies are strengthening market demand. Supportive regulatory
More news about: Allied Market Research
Mar 05, 2026, 09:30 ET Slingshot Biosciences Appoints Jim Snook as Senior Vice President, Global Sales
growth.Prior to Bio-Techne, Snook led the Americas commercial team at Miltenyi Biotec, growing the organization into the market leader in cell and gene therapy manufacturing and analytical solutions."Jim's appointment marks a pivotal moment for Slingshot Biosciences as we accelerate our global
More news about: Slingshot Biosciences
Mar 05, 2026, 09:30 ET Slingshot Biosciences Appoints Jim Snook as Senior Vice President, Global Sales
growth.Prior to Bio-Techne, Snook led the Americas commercial team at Miltenyi Biotec, growing the organization into the market leader in cell and gene therapy manufacturing and analytical solutions."Jim's appointment marks a pivotal moment for Slingshot Biosciences as we accelerate our global
More news about: Slingshot Biosciences
Mar 05, 2026, 09:00 ET SkylineDx Launches a Guideline-Informed Risk Assessment Initiative to Support SLNB Decision-Making in Early-Stage Melanoma
by clinicopathologic features alone or by results from commercially available gene expression profile tests ('Alternative GEP' assays) not recommended within current guideline direction.Merlin CP-GEP is the only gene expression profile assay prospectively validated in a large, multi-center blinded
More news about: SkylineDx
Mar 05, 2026, 08:00 ET Therna Announces Collaboration with Charles River to Advance Single-Patient Personalized RNA Therapeutics
later this year. For the newborn patient, Therna is designing small antisense oligonucleotides (ASOs) to increase gene expression, which is intended to restore the function of a defective gene, and Charles River will undertake the preclinical development of the candidate ASOs."Therna was founded on
More news about: Therna Biosciences
Mar 05, 2026, 07:56 ET GNTbm's self-developed anti-cancer new drug GNTbm-38 has obtained IND approval from the U.S. FDA for Phase I clinical trials
to possess excellent anticancer activity in tumor immunity. GNTbm-38 is an oral drug with dual unique activities of epigenetic regulation to control gene expression and immune activation, which is significantly different from the mechanism of previously developed epigenetic drugs and focuses mainly on
More news about: Great Novel Therapeutics Biotech & Medicals Corporation
Mar 05, 2026, 07:48 ET Chengdu Hi-Tech Zone rings with festival celebration
upstream and downstream supporting projects. In the medical and healthcare sector, it will focus on new frontiers such as innovative drugs and cell and gene therapy.Regarding social welfare, the zone will enhance its balanced and high-quality public service system, responding to the needs of residents
More news about: CHINA DAILY
Mar 05, 2026, 07:05 ET REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
deliver meaningful new medicines to patients in need through the curative potential of gene therapy."PROGRAM HIGHLIGHTS AND MILESTONESNeuromuscular Disease: RGX-202 is a potential best-in-class gene therapy for Duchenne muscular dystrophy (Duchenne). RGX-202 is designed to address
More news about: REGENXBIO Inc.
Mar 05, 2026, 07:00 ET Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey,
More news about: Insmed Incorporated
Mar 04, 2026, 18:27 ET PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026
or complex immune disorders. Hansa's proprietary IgG-cleaving enzyme technology platform to address serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy,
More news about: Hansa Biopharma AB
Mar 04, 2026, 18:25 ET PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026
or complex immune disorders. Hansa's proprietary IgG-cleaving enzyme technology platform to address serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy,
More news about: Hansa Biopharma AB
Mar 04, 2026, 18:01 ET Global Nanomedicine Market is Projected to Cross the USD 550 Billion Mark by 2034 as Advanced Drug Delivery Technologies Accelerate Adoption | DelveInsight
improves drug bioavailability, reduces side effects, and enhances precision in treatment. This has accelerated its adoption in oncology, immunotherapy, and gene therapy.Increased R&D Investment: Pharmaceutical and biotechnology companies, along with academic institutions, are substantially
More news about: DelveInsight Business Research, LLP
Mar 04, 2026, 09:00 ET REGENXBIO Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - RGNX
defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things,
More news about: Levi & Korsinsky, LLP